A
ABL Bio
Biotech research company focusing on the development of therapeutic drugs for immuno-oncology & neurodegenerative diseases
About ABL Bio
ABL Bio is a biotechnology company specializing in the development of bispecific antibody platforms aimed at treating intractable diseases, particularly in the field of oncology. The company serves pharmaceutical and biotech firms, leveraging its proprietary technology to create novel therapies that address unmet medical needs. Operating primarily in the global biotechnology market, ABL Bio's business model revolves around research and development, clinical trials, and strategic partnerships. Revenue is generated through licensing agreements, milestone payments, and royalties from successful drug candidates. The company's core values include life improvement, collaboration, innovation, and the pursuit of novel therapies.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2016
- Headquarters
- South Korea
- Listing
- IPO 2018
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
DSC Investment
Korea Investment Partners
Series B and later5 investors entered at this stage
Hana Financial Investment- QMQUAD Investment Management
- AMAlpenroute Asset Management
DS Asset Management
Eli Lilly
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about ABL Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ABL Bio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.